HDAC Cancer Research Results

HDAC, Histone deacetylases: Click to Expand ⟱
Source:
Type:
Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped.
-Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation.
-HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer.
-HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells.
-HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis.
-HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type.
-While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes.
-HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases.
-HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells.
Scientific Papers found: Click to Expand⟱
3237- EGCG,    (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression
- in-vivo, AD, NA
*HDAC↓, *Aβ↓, cognitive↑,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
3201- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*AntiCan↑, *cardioP↑, *neuroP↑, *BioAv↝, *BioAv↓, *BioAv↓, *Dose↝, *Half-Life↝, *BioAv↑, *BBB↑, *hepatoP↓, *other↓, *Inflam↓, *NF-kB↓, *AP-1↓, *iNOS↓, *COX2↓, *ROS↓, *RNS↓, *IL8↓, *JAK↓, *PDGFR-BB↓, *IGF-1R↓, *MMP2↓, *P53↓, *NRF2↑, *TNF-α↓, *IL6↓, *E2Fs↑, *SOD1↑, *SOD2↑, Casp3↑, Cyt‑c↑, PARP↑, DNMTs↓, Telomerase↓, Hif1a↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, TumCP↓, MAPK↓, HGF/c-Met↓, TIMP1↑, HDAC↓, MMP9↓, uPA↓, GlutMet↓, ChemoSen↑, chemoP↑,
5227- EMD,    Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy
- vitro+vivo, Nor, NA
*cardioP↑, HDAC↓, HDAC1↓, HDAC2↓, ac‑H3↑, Dose↝, BioAv↓,
1435- GEN,  SFN,    The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
DNMTs↓, HDAC↓, eff↑, TumCCA↑, HMTs↓, HDAC2↓, HDAC3↓, KLF4↓, hTERT/TERT↓,
2875- HNK,    Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo
- in-vitro, Lung, A549 - in-vitro, Lung, H1299 - in-vitro, Lung, H460 - in-vitro, SCC, H226
HDAC↓, tumCV↓, TumCCA↑, cycD1/CCND1↓, ac‑H3↑, ac‑H4↑, selectivity↑, CDK2↓, CDK4↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
1064- LT,  Cisplatin,    Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells
- vitro+vivo, Lung, LNM35 - in-vitro, CRC, HT-29 - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Casp3↑, Casp7↑, HDAC↓,
2927- LT,    Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells
- in-vitro, Cerv, HeLa
TumCMig↓, DNMTs↓, HDAC↓, HATs↓, ac‑H3↓, ac‑H4↓, MMP2↓, MMP9↓, HO-1↓, E-cadherin↑, EZH2↓, HER2/EBBR2↓, IL18↓, IL8↓, IL2↓,
2915- LT,    Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells
- in-vitro, Colon, HT29 - in-vitro, CRC, SNU-407 - in-vitro, Nor, FHC
DNMTs↓, TET1↑, NRF2↑, HDAC↓, tumCV↓, BAX↑, Casp9↑, Casp3↑, Bcl-2↓, ROS↓, GSS↑, Catalase↑, HO-1↑, DNMT1↓, DNMT3A↓, TET1↑, TET3↑, TET2↓, P53↑, P21↑,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
1196- MAG,    2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression
- in-vitro, HCC, NA
TumCG↓, TumCMig↓, TumCI↓, TumCCA↑, HDAC↓,
998- PB,    Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect
- in-vivo, NA, NA
p‑PDH↓, PDH↑, PDK1↓, HDAC↓, Glycolysis↓, MMP↓, Apoptosis↑,
2052- PB,    Lipid-regulating properties of butyric acid and 4-phenylbutyric acid: Molecular mechanisms and therapeutic applications
- Review, NA, NA
*HDAC↓, *Half-Life↑, *Half-Life↑, *lipoGen↓, *ER Stress↓, *FAO↑, *ROS↓, *BioAv↑,
2054- PB,    Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis
- in-vitro, EC, ISH - in-vitro, EC, HEC1B
Ferroptosis↑, xCT↓, RBM3↑, HDAC↓, ROS↑,
2061- PB,  Chemo,    Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells
- in-vitro, PC, PANC1 - in-vitro, PC, COLO357 - in-vitro, PC, Bxpc-3
HDAC↓, Apoptosis↑, eff↑, selectivity↑, TumCCA↑, eff↑, selectivity↑,
2064- PB,  Rad,    Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Pca, LNCaP
Bcl-xL↓, Cav1↓, VEGF↓, RadioS↑, chemoP↑, HDAC↓, *toxicity↓, Diff↑, Prot↓,
2067- PB,    Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer
- in-vitro, PC, NA
HDAC↓, HATs↑,
2074- PB,  Chemo,    The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
- in-vitro, Lung, A549 - in-vitro, Lung, Calu-6 - in-vitro, Lung, H1650
TumCG↓, eff↑, ChemoSen↑, HDAC↓,
2075- PB,  Chemo,    Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Colorectal Cancer after Failure of Second-Line Therapy—A Potential Strategy for Improved Survival
- Trial, CRC, NA
OS↑, HDAC↓,
2077- PB,    Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells
- in-vitro, Liver, HUH7
miR-22↑, SIRT1↓, ROS↑, Cyt‑c↑, Casp3↑, eff↓, TumCG↓, TumCP↓, HDAC↓, SIRT1↓, CD44↓, proMMP2↓, MMP↓, SOD↓,
2048- PB,    Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo
- in-vitro, OS, CAL27 - in-vitro, Oral, HSC3 - in-vitro, OS, SCC4 - in-vivo, NA, NA
*NH3↓, *HDAC↓, *ER Stress↓, Apoptosis?, Bcl-2↓, cl‑Casp3↑, TGF-β↑, N-cadherin↓, E-cadherin↑, TumVol↓, eff↑,
2026- PB,    Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study
- Trial, GBM, NA
Dose↝, Dose↑, Dose↝, OS↑, HDAC↓, TumCCA↑, P21↑, other↝, BioAv↑, eff↑,
2027- PB,    Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
- Trial, Var, NA
TumCG↓, Dose↝, toxicity↓, Dose↝, HDAC↓, OS↑,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,
2029- PB,    Phenylbutyric Acid: simple structure - multiple effects
- Review, Var, NA
NH3↓, HDAC↓, ChemChap↑,
2030- PB,    4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor
- Review, Nor, NA
*HDAC↓, *neuroP↑, *ChemChap↑,
2031- PB,    Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model
- in-vivo, AD, NA
*neuroP↑, *HDAC↓, *ChemChap↑,
2035- PB,    Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease
- in-vitro, Nor, glial - in-vivo, NA, NA
*ROS↓, *Inflam↑, *P21↓, *antiOx↑, *GSH↑, *NF-kB↓, *neuroP↑, *HDAC↓, *iNOS↓, *TNF-α↓, *IL1β↓, *LDL↓, ROS↓,
2039- PB,    TXNIP mediates the differential responses of A549 cells to sodium butyrate and sodium 4‐phenylbutyrate treatment
- in-vitro, Lung, A549 - in-vitro, Nor, HEK293
TXNIP↑, Casp3↑, Casp7↑, mt-ROS↑, GlucoseCon↓, TumCP↓, TumCD↑, IGF-2↑, HDAC↓, ROS⇅,
2049- PB,    Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
- Review, Var, NA
HDAC↓, ac‑H3↑, ac‑H4↑, ac‑H3↑, eff↝, toxicity↓,
2042- PB,    Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury
- in-vitro, Nor, NA
*HDAC↓, *toxicity↓, *LDH↓, *SOD2↑, *ROS↓, *cardioP↑, *antiOx↑,
2043- PB,  Cisplatin,    Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
- in-vitro, HNSCC, UM-SCC-1
ChemoSen↑, eff↑, HDAC↓, BRCA1↓, RadioS↑,
2045- PB,    Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line
- in-vitro, GBM, LN229 - in-vitro, GBM, LN-18
HDAC↓, TumCG↓, TumCCA↑, P21↑, Bcl-2↓, Bcl-xL↓, BioAv↑,
2046- PB,    Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-468 - in-vitro, Nor, MCF10
Apoptosis↑, i-ROS?, Casp↑, MMP?, selectivity↑, *ROS∅, HDAC↓, DNArepair↓, Casp3↑, Casp8↑, *toxicity↓, TumCCA↑,
1660- PBG,    Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents
- Review, Var, NA
MMPs↓, angioG↓, TumMeta↓, TumCCA↑, Apoptosis↑, ChemoSideEff↓, eff∅, HDAC↓, PTEN↑, p‑PTEN↓, p‑Akt↓, Casp3↑, p‑ERK↑, p‑FAK↑, Dose?, Akt↓, GSK‐3β↓, FOXO3↓, eff↑, IL2↑, IL10↑, NF-kB↓, VEGF↓, mtDam↑, ER Stress↑, AST↓, ALAT↓, ALP↓, COX2↓, eff↑, Bax:Bcl2↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1/CCNA1↓, CycB/CCNB1↓, CDK2↓, P21↑, p27↑, hTERT/TERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
4921- PEITC,    The Potential Use of Phenethyl Isothiocyanate for Cancer Prevention
- Review, Var, NA
antiOx↑, Inflam↓, AntiCan↑, TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, HDAC↓, Risk↓,
4928- PEITC,    Dietary phytochemical PEITC restricts tumor development via modulation of epigenetic writers and erasers
- vitro+vivo, Colon, SW-620
Risk↓, HDAC↓, TumW↓, TumCG↓, AP-1↓, cAMP↓, NF-kB↓, BMI1↓, SUZ12↓, EZH2↓, selectivity↑,
1938- PL,    Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation
- Study, PSA, NA - in-vivo, NA, NA
ROS↑, Apoptosis↑, MMP↓, TumCCA↑, DNAdam↑, STAT3↓, Akt↓, PCNA↓, Ki-67↓, cycD1/CCND1↓, Bcl-2↓, K17↓, HDAC↓, ROS↑, *IL1β↓, *IL6↓, *TNF-α↓, *IL17↓, *IL22↓,
3357- QC,    The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes
- in-vitro, AML, HL-60 - NA, NA, U937
DNMT1↓, DNMT3A↓, HDAC↓, ac‑H3↑, ac‑H4↑, BAX↑, APAF1↑, BNIP3↑, STAT3↑,
3359- QC,    Quercetin modifies 5′CpG promoter methylation and reactivates various tumor suppressor genes by modulating epigenetic marks in human cervical cancer cells
- in-vitro, Cerv, HeLa
DNMTs↓, HDAC↓, HMTs↓, DNMT3A↓, EZH2↓, HDAC1↓, HDAC2↓, HDAC6↓, HDAC11↓, G9a↓, TIMP3↑, PTEN↑, SOCS1↑,
3360- QC,    Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy
- Review, Var, NA
HDAC↓, DNMTs↓, HMTs↓, Let-7↑, NOTCH↓,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
1506- RES,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
DNMTs↓, BRCA1↑, HDAC↓, SIRT1↑, p300↓, survivin↓, HDAC1↓, HDAC3↓, HDAC8↓,
882- RES,    Resveratrol: A Double-Edged Sword in Health Benefits
- Review, NA, NA
AntiTum↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, Bcl-xL↓, P53↑, NAF1↓, NRF2↑, ROS↑, Apoptosis↑, HDAC↓, TumCCA↑, TumAuto↑, angioG↓, iNOS↓,
883- RES,    Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
HDAC↓, TumCCA↑, Apoptosis↑, angioG↓, ROS↑,
2040- SAHA,    The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
- in-vitro, Pca, LNCaP - in-vitro, CRC, T24/HTB-9 - in-vitro, BC, MCF-7
HDAC↓, TumCG↓, Diff↑, Apoptosis↑, TXNIP↑,
4198- SFN,    Sulforaphane epigenetically enhances neuronal BDNF expression and TrkB signaling pathways
- vitro+vivo, AD, NA
*TrkB↑, *CREB↑, CaMKII ↑, *ERK↑, *ac‑H3↑, *ac‑H4↑, *HDAC↓, *HDAC2↓, *BDNF↑,

Showing Research Papers: 51 to 100 of 147
Prev Page 2 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 147

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   Catalase↓, 1,   Catalase↑, 1,   CYP1A1↓, 1,   Ferroptosis↑, 1,   GPx↓, 1,   GSH↓, 2,   GSR↓, 1,   GSS↑, 1,   GSTs↓, 1,   HO-1↓, 2,   HO-1↑, 1,   lipid-P↓, 1,   NAF1↓, 1,   NQO1↓, 1,   NRF2↓, 1,   NRF2↑, 3,   ROS↓, 4,   ROS↑, 13,   ROS⇅, 2,   i-ROS?, 1,   mt-ROS↑, 1,   SIRT3↑, 1,   SOD↓, 2,   SOD2↓, 1,   VitC↓, 1,   VitE↓, 1,   xCT↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   MMP?, 1,   MMP↓, 5,   mtDam↑, 1,   c-Raf↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 1,   ATG7↑, 1,   cAMP↓, 1,   Cav1↓, 1,   cMyc↓, 2,   GlucoseCon↓, 2,   GlutMet↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   NH3↓, 1,   PDH↑, 1,   p‑PDH↓, 1,   PDK1↓, 1,   cl‑PPARα↓, 1,   SIRT1↓, 3,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis?, 1,   Apoptosis↑, 11,   ASK1↑, 1,   Bak↑, 1,   BAX↑, 7,   BAX⇅, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 9,   Bcl-xL↓, 4,   Casp↑, 1,   Casp1↓, 1,   Casp3↓, 1,   Casp3↑, 13,   cl‑Casp3↑, 1,   Casp7↑, 2,   Casp8↑, 3,   Casp9↑, 5,   cl‑Casp9↑, 1,   cFLIP↓, 2,   Cyt‑c↑, 5,   Cyt‑c↝, 1,   Diablo↑, 2,   DR5↑, 2,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 1,   HGF/c-Met↓, 2,   hTERT/TERT↓, 2,   iNOS↓, 2,   JNK↓, 1,   JNK↑, 2,   p‑JNK↑, 1,   MAPK↓, 3,   Mcl-1↓, 1,   Mcl-1↑, 1,   MDM2↑, 1,   p‑MDM2↓, 1,   p27↑, 2,   p‑p38↑, 2,   survivin↓, 4,   Telomerase↓, 3,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

CaMKII ↑, 1,   EF-1α↓, 1,   HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

cJun↑, 1,   EZH2↓, 3,   H3↓, 1,   H3↑, 1,   ac‑H3↓, 1,   ac‑H3↑, 6,   H4↓, 1,   H4↑, 1,   ac‑H4↓, 1,   ac‑H4↑, 4,   HATs↓, 2,   HATs↑, 2,   other?, 1,   other↝, 1,   pRB↑, 1,   Prot↓, 1,   TET3↑, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

ChemChap↑, 1,   CHOP↑, 3,   cl‑CHOP↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 4,   GRP78/BiP↓, 1,   GRP78/BiP↑, 2,   HSP27↑, 1,   p‑PERK↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   BNIP3↑, 1,   LC3II↑, 2,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

BRCA1↓, 1,   BRCA1↑, 1,   DNAdam↑, 2,   DNArepair↓, 2,   DNMT1↓, 2,   DNMT3A↓, 3,   DNMTs↓, 9,   G9a↓, 1,   p16↑, 1,   P53↑, 6,   PARP↑, 2,   cl‑PARP↑, 1,   PARP1↑, 1,   PCNA↓, 5,  

Cell Cycle & Senescence ⓘ

CDK2↓, 4,   CDK4↓, 3,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   P21?, 1,   P21↑, 6,   p‑RB1↓, 1,   TumCCA↑, 16,  

Proliferation, Differentiation & Cell State ⓘ

BMI1↓, 1,   CD133↓, 2,   CD34↓, 1,   CD44↓, 1,   cFos↑, 1,   p‑cMET↑, 1,   CSCs↓, 1,   Diff↑, 2,   EMT↓, 3,   ERK↓, 1,   ERK↑, 1,   p‑ERK↓, 1,   p‑ERK↑, 1,   FOXO↑, 1,   FOXO3↓, 1,   GSK‐3β↓, 1,   HDAC↓, 42,   HDAC1↓, 3,   HDAC11↓, 1,   HDAC2↓, 3,   HDAC3↓, 2,   HDAC6↓, 1,   HDAC8↓, 1,   HMTs↓, 3,   IGF-2↑, 1,   IGFBP3↑, 1,   KLF4↓, 1,   Let-7↑, 1,   mTOR↓, 2,   p‑mTOR↓, 1,   mTORC1↓, 1,   Nanog↓, 1,   Nestin↓, 2,   NOTCH↓, 1,   NOTCH1↓, 2,   NOTCH3↓, 1,   OCT4↓, 1,   p300↓, 1,   PI3K↓, 2,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 4,   p‑PTEN↓, 1,   RAS↑, 1,   Shh↓, 1,   SOX2↓, 1,   p‑Src↓, 1,   STAT3↓, 4,   STAT3↑, 1,   p‑STAT3↓, 1,   p‑STAT6↓, 1,   SUZ12↓, 1,   TumCG↓, 7,  

Migration ⓘ

AntiAg↓, 1,   AP-1↓, 2,   AXL↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   CLDN2↓, 1,   CXCL12↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 3,   FAK↓, 3,   p‑FAK↑, 1,   ITGB1↓, 1,   Ki-67↓, 2,   MET↓, 1,   p‑MET↓, 1,   miR-22↑, 1,   MMP2↓, 4,   proMMP2↓, 1,   MMP9↓, 4,   MMPs↓, 6,   N-cadherin↓, 3,   PDGF↓, 1,   PKCδ↓, 1,   Rac1↓, 1,   Rho↓, 1,   Snail↓, 2,   SOX4↓, 1,   TET1↑, 2,   TGF-β↓, 1,   TGF-β↑, 1,   TIMP1↑, 1,   TIMP2↑, 1,   TIMP3↑, 1,   TSP-1↑, 1,   TumCI↓, 3,   TumCMig↓, 4,   TumCP↓, 5,   TumMeta↓, 4,   Twist↓, 1,   TXNIP↑, 2,   Tyro3↓, 1,   uPA↓, 3,   Vim↓, 1,   Vim↑, 1,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 2,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 5,   EGFR↓, 3,   EGFR↑, 1,   Hif1a↓, 5,   LOX1↓, 1,   NO↓, 1,   NO↑, 1,   VEGF↓, 8,   VEGFR2↓, 2,  

Barriers & Transport ⓘ

GLUT1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX2↓, 4,   COX2↑, 1,   CXCR4↓, 2,   ICAM-1↓, 1,   Igs↑, 1,   IKKα↓, 2,   IL10↓, 1,   IL10↑, 1,   IL18↓, 1,   IL2↓, 1,   IL2↑, 2,   IL6↓, 2,   IL8↓, 1,   Inflam↓, 1,   NF-kB↓, 6,   NK cell↑, 1,   p65↓, 1,   p‑p65↓, 1,   PD-1↓, 1,   PGE2↓, 1,   SOCS1↑, 1,   TNF-α↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 2,   ER(estro)↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 3,   ChemoSen↑, 8,   Dose?, 2,   Dose↑, 1,   Dose↝, 7,   eff↓, 2,   eff↑, 15,   eff↝, 1,   eff∅, 1,   Half-Life↓, 1,   Half-Life↝, 1,   RadioS↑, 4,   selectivity↑, 8,   TET2↓, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AR↓, 2,   AST↓, 1,   BMPs↑, 1,   BRCA1↓, 1,   BRCA1↑, 1,   CEA↓, 1,   EGFR↓, 3,   EGFR↑, 1,   EZH2↓, 3,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 2,   IL6↓, 2,   Ki-67↓, 2,   NSE↓, 1,   RBM3↑, 1,   SUZ12↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cachexia↓, 1,   chemoP↑, 4,   ChemoSideEff↓, 1,   cognitive↑, 1,   K17↓, 1,   OS↑, 4,   Risk↓, 2,   toxicity↓, 2,   TumVol↓, 1,   TumW↓, 1,  
Total Targets: 343

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 6,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 3,   GSTs↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   NRF2↑, 2,   RNS↓, 1,   ROS↓, 8,   ROS∅, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   CREB↑, 1,   FAO↑, 1,   LDH↓, 1,   LDL↓, 1,   lipoGen↓, 1,   NADPH↓, 1,   NH3↓, 1,  

Cell Death ⓘ

Casp3↓, 2,   iNOS↓, 2,  

Transcription & Epigenetics ⓘ

ac‑H3↑, 1,   ac‑H4↑, 1,   other↓, 1,  

Protein Folding & ER Stress ⓘ

ChemChap↑, 2,   ER Stress↓, 2,  

DNA Damage & Repair ⓘ

P53↓, 1,  

Cell Cycle & Senescence ⓘ

E2Fs↑, 1,   P21↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↑, 1,   HDAC↓, 8,   HDAC2↓, 1,   IGF-1R↓, 1,  

Migration ⓘ

AP-1↓, 1,   MMP2↓, 1,   p‑Rac1↓, 1,  

Angiogenesis & Vasculature ⓘ

PDGFR-BB↓, 1,  

Barriers & Transport ⓘ

BBB↑, 2,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IKKα↑, 1,   IL10↓, 1,   IL10↑, 1,   IL17↓, 1,   IL1β↓, 3,   IL22↓, 1,   IL6↓, 3,   IL8↓, 1,   Inflam↓, 4,   Inflam↑, 1,   JAK↓, 1,   NF-kB↓, 3,   PGE2↓, 1,   TNF-α↓, 5,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,   TrkB↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 2,   BioAv↝, 1,   Dose↝, 1,   eff↑, 1,   Half-Life↑, 2,   Half-Life↝, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   IL6↓, 3,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cardioP↑, 4,   hepatoP↓, 1,   hepatoP↑, 1,   neuroP↑, 6,   RenoP↑, 1,   toxicity↓, 3,  
Total Targets: 79

Scientific Paper Hit Count for: HDAC, Histone deacetylases
33 Sulforaphane (mainly Broccoli)
23 Phenylbutyrate
14 Thymoquinone
12 Butyrate
10 EGCG (Epigallocatechin Gallate)
7 Apigenin (mainly Parsley)
4 Chrysin
4 Curcumin
4 Chemotherapy
4 Luteolin
4 Quercetin
3 Berberine
3 Boron
3 Honokiol
3 Resveratrol
3 Silymarin (Milk Thistle) silibinin
2 Ashwagandha(Withaferin A)
2 Atorvastatin
2 Radiotherapy/Radiation
2 Cisplatin
2 Propolis -bee glue
2 Phenethyl isothiocyanate
1 3-bromopyruvate
1 Allicin (mainly Garlic)
1 Acetyl-l-carnitine
1 alpha Linolenic acid
1 Andrographis
1 Betulinic acid
1 diet FMD Fasting Mimicking Diet
1 Emodin
1 Genistein (soy isoflavone)
1 Magnolol
1 Piperlongumine
1 Vorinostat
1 diet Plant based
1 Gemcitabine (Gemzar)
1 Vitamin D3
1 doxorubicin
1 Selenite (Sodium)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:140  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page